Forgot your password?

Forgot your username?

database > company
Bionetek
Medical Devices & Tech
3445 Fletcher Ave.
El Monte, CA 91731 USA
phone:626-456-8080
fax:
Symbol Private
Founded 2005
Employees 5
www.bionetek.com
Research Sector Medical Devices & Tech
Summary Description
Early Cardiac Diagnostic System
Management
Edward Chen, CEO
Keywords
cardiac dysfunctions, cardiology, heart disease, early detection, CAD, coronary artery disease, preventive cardiology, silent ischemia, ECG, EKG, electrocardiography, coronary angiogram.

Comment | Printable Version | Modify profile |
Updated: May 16, 2011

Description
Bionetek develops and markets proprietary 12-lead Crebrocardiography (CCG) technology, allowing for the early diagnosis of cardiac abnormalities.
Products / Services
Combining advanced cardiac mathematical modeling with a non-invasive and stress free 10 minute ECG-style test, the CARDx ECD diagnostic system can detect obstructive coronary artery disease (CAD) with up to 94% accuracy compared to conventional coronary angiograms. Based on a clinical reference database of 30,000+ cases, the current system can also detect and differentiate various heart dysfunctions.
Technology / Differentiation
The 12-lead CCG core technology housed in the CARDx ECD system is rooted in quantum power spectrum and biocybernetic principles, which have been used widely in the aerospace, nuclear, and electronics industries for years.
Market / Customers
Heart diseases are responsible for over 800,000 annual deaths in the United States and over 7 million worldwide. Whether for triage of patients with chest pain in the emergency room or for general coronary artery disease (CAD) screening purposes, the CARDx ECD system is for all the health care professionals who are interested in preventive cardiac care. The company's research topics and applications include:
  • CAD/ischemia detection in comparison to various diagnostic modalities (coronary angiography, PET/angiography, etc.)
  • Emergency Room/Department: triage of patients with chest pain
  • Women and Heart Disease
Funding
Bionetek is not receiving any funding from VCs, but is open to considering external financing from the right investor.
Status
Bionetek launched a new website for the CARDx ECD in February 2009. The company has conducted several clinical trials in Europe and is in the process of identifying appropriate research facilities for clinical trials in the U.S. FDA Approval is expected by the end of 2009.